Patent ID: 11857574
Assignee: CRISPR THERAPEUTICS AG
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 15:
16. The population of immune cells of claim 15, wherein:
(i) the disrupted Reg1 gene is generated by a gRNA comprising a spacer sequence set forth as SEQ ID NO: 52;
(ii) the disrupted TGFBRII gene is generated by a gRNA comprising a spacer sequence set forth as SEQ ID NO: 314;
(iii) the disrupted TRAC gene is generated by a gRNA comprising a spacer sequence set forth as of SEQ ID NO: 61;
(iv) the disrupted β2M gene is generated by a gRNA comprising a spacer sequence set forth as SEQ ID NO: 65, and
(v) the disrupted CD70 gene is generated by a spacer sequence set forth as SEQ ID NO: 57.